Published in Gene Therapy Weekly, October 26th, 2006
These results were obtained in genetic studies of two separate prospective randomized clinical trials assessing the effect of pravastatin on prevention of MI and CHD: the Cholesterol and Recurrent Events study (CARE) and West of Scotland Coronary Prevention Study (WOSCOPS). The risk of coronary events associated with the FCAR Asp92Asn polymorphism in both CARE and WOSCOPS was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.